Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Neuralstem licenses innovative stem sell drug delivery system

Neuralstem : 22 November, 2007  (New Product)
Neuralstem has exclusively licensed the Spinal Multisegmental Cell and Drug Delivery System invented by Dr Martin Marsala at the University of California, San Diego (UCSD).
The exclusive, worldwide licence to Neuralstem covers all fields of use and includes the right to grant sublicenses. Under the terms of the agreement, UCSD will be eligible for milestone payments and royalties and Neuralstem will assume the cost of development, manufacture and approval of the product.

'Neuralstem is actively pursuing human clinical trials for its human spinal cord stem cells to treat Ischemic Paraplegia, ALS and Traumatic Spinal Cord Injury,' said Neuralstem CEO Richard Garr. 'All three indications require delivering our cells directly into the spinal cord. We believe that Dr Marsala's injection device will allow for a minimally invasive injection of the cells into the spinal cord, thus significantly reducing the risk of the surgery to any patients receiving cell or drug therapy administered directly into the spinal cord.'

'The device provides a unique method for delivering cells horizontally along the length of the spinal cord which will reduce the number of entry sites needed for therapeutic intervention. We believe that this will greatly enhance the likelihood of success for treating many indications,' said Dr Marsala.

'Neuralstem has not only shown a strong commitment to moving their spinal cord stem cells into the clinic, but to creating a therapy that can be broadly and safely delivered. We are excited to have them as our exclusive licensee for this important technology.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo